Abhimanyu Verma Sells 6,944 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

Posted by Geri Gentry on Jun 28th, 2026

SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) CTO Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $5.51, for a total value of $38,261.44. Following the completion of the transaction, the chief technology officer directly owned 197,456 shares in the company, valued at $1,087,982.56. This trade represents a 3.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abhimanyu Verma also recently made the following trade(s):

On Tuesday, April 7th, Abhimanyu Verma sold 1,030 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total value of $5,016.10.
On Monday, April 6th, Abhimanyu Verma sold 2,519 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.86, for a total transaction of $12,242.34.

SOPHiA GENETICS Stock Up 1.1%

Shares of NASDAQ SOPH opened at $5.75 on Friday. The firm’s fifty day moving average is $5.07 and its 200 day moving average is $4.92. SOPHiA GENETICS SA has a 52 week low of $2.81 and a 52 week high of $5.94. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. The company has a market cap of $482.37 million, a price-to-earnings ratio of -11.06 and a beta of 0.98.

SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $21.69 million for the quarter, compared to analysts’ expectations of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares during the period. Akre Capital Management LLC boosted its holdings in shares of SOPHiA GENETICS by 66.2% during the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after buying an additional 1,481,636 shares in the last quarter. Hodges Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS in the 1st quarter worth about $2,157,000. Royce & Associates LP bought a new position in shares of SOPHiA GENETICS in the 4th quarter worth about $2,009,000. Finally, Sei Investments Co. bought a new position in shares of SOPHiA GENETICS in the 1st quarter worth about $1,772,000. Institutional investors own 31.59% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. BTIG Research reaffirmed a “buy” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $7.50.

Get Our Latest Stock Report on SOPH

SOPHiA GENETICS Company Profile

(Get Free Report)

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.